Published in Drug Law Weekly, February 8th, 2005
On December 15, 2004, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Lunesta for the treatment of insomnia. As expected, the FDA recommended that Lunesta, like all other nonbenzodiazepine hypnotics, be classified as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA).
The federal government's administrative process for formally classifying Lunesta as a Schedule IV controlled substance is not yet complete. Because of uncertainties...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.